Article

FDA approves ISTA product, asked to evaluate another

On May 6 the FDA approved ISTA Pharmaceutical's new drug application (NDA) for lyophilized, ovine hyaluronidase for injection (Vitrase) for use as a spreading agent to facilitate the dispersion and absorption of other drugs.

Related Videos
2 experts are featured in this series.
Related Content
Advancing Fuchs dystrophy care: Longterm success of descemet stripping only
December 26th 2024

Advancing Fuchs dystrophy care: Longterm success of descemet stripping only

2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco
December 13th 2024

California dreaming: 2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco

Advancements in ocular drug delivery
December 26th 2024

Advancements in ocular drug delivery

EnVision Summit 2025: Advancing Ophthalmology and Optometry Together
November 19th 2024

Connect, learn, and innovate in a family-friendly atmosphere: What to expect at EnVision Summit 2025

Study: Diabetes does not significantly impact outcomes of epiretinal membrane surgery
Published: December 26th 2024 | Updated: December 26th 2024

Study: Diabetes does not significantly impact outcomes of epiretinal membrane surgery

NYU Grossman School of Medicine launches Journal Club series with expert insights on ophthalmology research
December 26th 2024

NYU Grossman School of Medicine launches Journal Club series with expert insights on ophthalmology research

© 2024 MJH Life Sciences

All rights reserved.